<DOC>
	<DOC>NCT02166398</DOC>
	<brief_summary>A randomized, open-label, single dose, two-way crossover clinical trial to compare the safety, pharmacokinetic profiles of UI15AML055MT and Amosartan® tablet 5/50 mg after a single oral administration in healthy male volunteers</brief_summary>
	<brief_title>A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of UI15AML055MT and Amosartan® Tablet 5/50 mg After a Single Oral Administration in Healthy Male Volunteers</brief_title>
	<detailed_description>A randomized, open-label, single dose, two-way crossover clinical trial to compare the safety, pharmacokinetic profiles of UI15AML055MT and Amosartan® tablet 5/50 mg after a single oral administration in healthy male volunteers</detailed_description>
	<criteria>Patients over 20 under 45 years of age BMI state over 19 under 27 mean sit SBP≥100mmHg or mean sit DBP≥150mmHg at screening mean sit SBP≥65mmHg or mean sit DBP≥95mmHg at screening Patients showed clinically significant hematological finding, patients with renal diseases (serum creatinine), patients with hepatic disease (ALT or AST) History of alcohol or drug abuse Positive to pregnancy test, nursing mother, has an intention on pregnancy Considered by investigator as not appropriate to participate in the clinical study with othe reason</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Amlodipine basylate, Losartan potassium</keyword>
</DOC>